A new study reveals the mechanisms behind repetitive transcranial magnetic stimulation's effect on the brain in the treatment of depression.
Repetitive transcranial magnetic stimulation helped reduce cannabis use by up to 60% in those with schizophrenia who have cannabis use disorder.
Repetitive transcranial magnetic stimulation (rTMS) can be used to modulate brain rhythms and cognitive behaviors related to "giving up" during problem-solving tasks.
Repetitive transcranial magnetic stimulation (rTMS) applied to the left prefrontal cortex can improve episodic memory performance by reducing the power of low frequency of brain waves during memory formation.
Researchers apply DOT neuroimaging to patients receiving repetitive transcranial magnetic stimulation (rTMS) for depression to better understand the effectiveness of the brain stimulation for the treatment of the disorder.
Non-invasive brain stimulation technology may enhance the human system's ability for rapid and adaptive decision making.
Applying repetitive transcranial magnetic stimulation (rTMS) to the prefrontal cortex helps improve performance in working memory tasks for both young and older subjects. The findings could provide a potential new treatment option for those suffering from Alzheimer's disease and other memory-related problems.
A new study combines hundreds of brain scans of patients with OCD and pinpoints problems with error processing in the brain that leads to repetitive behaviors.
When it comes to using rTMS to treat neurological and psychiatric conditions, less might be more, researchers say. The study reports fewer stimulations are required to prevent neurons from ceasing to respond.
Personalized rTMS treatments could be revolutionary in helping combat neuropsychiatric disorders, researchers say.
According to researchers, 40% of people with treatment resistant depression who received rTMS no longer had suicidal thoughts following treatment.
Researchers report intermittent theta burst stimulation can help to alleviate the symptoms of major depressive disorder. 49% of patients who received the treatment reported a significant decrease in symptoms, with 32% reporting remission of depression.
